These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 31443984)

  • 1. Sympathetic and renin-angiotensin-aldosterone system activation in heart failure with preserved, mid-range and reduced ejection fraction.
    Vergaro G; Aimo A; Prontera C; Ghionzoli N; Arzilli C; Zyw L; Taddei C; Gabutti A; Poletti R; Giannoni A; Mammini C; Spini V; Passino C; Emdin M
    Int J Cardiol; 2019 Dec; 296():91-97. PubMed ID: 31443984
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Associations With and Prognostic and Discriminatory Role of N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure With Preserved Versus Mid-range Versus Reduced Ejection Fraction.
    Savarese G; Orsini N; Hage C; Dahlström U; Vedin O; Rosano GMC; Lund LH
    J Card Fail; 2018 Jun; 24(6):365-374. PubMed ID: 29597053
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comprehensive population-based characterization of heart failure with mid-range ejection fraction.
    Koh AS; Tay WT; Teng THK; Vedin O; Benson L; Dahlstrom U; Savarese G; Lam CSP; Lund LH
    Eur J Heart Fail; 2017 Dec; 19(12):1624-1634. PubMed ID: 28948683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bio-profiling and bio-prognostication of chronic heart failure with mid-range ejection fraction.
    Moliner P; Lupón J; Barallat J; de Antonio M; Domingo M; Núñez J; Zamora E; Galán A; Santesmases J; Pastor C; Bayes-Genis A
    Int J Cardiol; 2018 Apr; 257():188-192. PubMed ID: 29415801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mortality associated with heart failure with preserved vs. reduced ejection fraction in a prospective international multi-ethnic cohort study.
    Lam CSP; Gamble GD; Ling LH; Sim D; Leong KTG; Yeo PSD; Ong HY; Jaufeerally F; Ng TP; Cameron VA; Poppe K; Lund M; Devlin G; Troughton R; Richards AM; Doughty RN
    Eur Heart J; 2018 May; 39(20):1770-1780. PubMed ID: 29390051
    [TBL] [Abstract][Full Text] [Related]  

  • 6. N-terminal pro-B-type natriuretic peptide in chronic heart failure: The impact of sex across the ejection fraction spectrum.
    Faxén UL; Lund LH; Orsini N; Strömberg A; Andersson DC; Linde C; Dahlström U; Savarese G
    Int J Cardiol; 2019 Jul; 287():66-72. PubMed ID: 31005415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Utilizing NT-proBNP for Eligibility and Enrichment in Trials in HFpEF, HFmrEF, and HFrEF.
    Savarese G; Orsini N; Hage C; Vedin O; Cosentino F; Rosano GMC; Dahlström U; Lund LH
    JACC Heart Fail; 2018 Mar; 6(3):246-256. PubMed ID: 29428439
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence and Prognostic Implications of Longitudinal Ejection Fraction Change in Heart Failure.
    Savarese G; Vedin O; D'Amario D; Uijl A; Dahlström U; Rosano G; Lam CSP; Lund LH
    JACC Heart Fail; 2019 Apr; 7(4):306-317. PubMed ID: 30852236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sympathetic activation and outcomes in chronic heart failure: Does the neurohormonal hypothesis apply to mid-range and preserved ejection fraction patients?
    Jimenez-Marrero S; Moliner P; Rodríguez-Costoya I; Enjuanes C; Alcoberro L; Yun S; Gonzalez-Costello J; Garay A; Tajes M; Calero E; Hidalgo E; Guerrero C; García-Romero E; Díez-López C; Cainzos-Achirica M; Comin-Colet J
    Eur J Intern Med; 2020 Nov; 81():60-66. PubMed ID: 32718877
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reductions in N-Terminal Pro-Brain Natriuretic Peptide Levels Are Associated With Lower Mortality and Heart Failure Hospitalization Rates in Patients With Heart Failure With Mid-Range and Preserved Ejection Fraction.
    Savarese G; Hage C; Orsini N; Dahlström U; Perrone-Filardi P; Rosano GM; Lund LH
    Circ Heart Fail; 2016 Nov; 9(11):. PubMed ID: 28029640
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characteristics and long-term prognosis of patients with heart failure and mid-range ejection fraction compared with reduced and preserved ejection fraction: a systematic review and meta-analysis.
    Lauritsen J; Gustafsson F; Abdulla J
    ESC Heart Fail; 2018 Aug; 5(4):685-694. PubMed ID: 29660263
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Age-dependent differences in clinical phenotype and prognosis in heart failure with mid-range ejection compared with heart failure with reduced or preserved ejection fraction.
    Chen X; Savarese G; Dahlström U; Lund LH; Fu M
    Clin Res Cardiol; 2019 Dec; 108(12):1394-1405. PubMed ID: 30980205
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Contemporary epidemiology and treatment of hospitalized heart failure patients in real clinical practice in China].
    Wang H; Li YY; Chai K; Zhang W; Li XL; Dong YG; Zhou JM; Huo Y; Yang JF
    Zhonghua Xin Xue Guan Bing Za Zhi; 2019 Nov; 47(11):865-874. PubMed ID: 31744275
    [No Abstract]   [Full Text] [Related]  

  • 14. Biomarkers in acutely decompensated heart failure with preserved or reduced ejection fraction.
    Bishu K; Deswal A; Chen HH; LeWinter MM; Lewis GD; Semigran MJ; Borlaug BA; McNulty S; Hernandez AF; Braunwald E; Redfield MM
    Am Heart J; 2012 Nov; 164(5):763-770.e3. PubMed ID: 23137508
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heart failure with mid-range ejection fraction: a distinct clinical entity? Insights from the Trial of Intensified versus standard Medical therapy in Elderly patients with Congestive Heart Failure (TIME-CHF).
    Rickenbacher P; Kaufmann BA; Maeder MT; Bernheim A; Goetschalckx K; Pfister O; Pfisterer M; Brunner-La Rocca HP;
    Eur J Heart Fail; 2017 Dec; 19(12):1586-1596. PubMed ID: 28295985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Different relationships between pulse pressure and mortality in heart failure with reduced, mid-range and preserved ejection fraction.
    Teng TK; Tay WT; Dahlstrom U; Benson L; Lam CSP; Lund LH
    Int J Cardiol; 2018 Mar; 254():203-209. PubMed ID: 29407092
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atrial Fibrillation in Heart Failure With Preserved, Mid-Range, and Reduced Ejection Fraction.
    Sartipy U; Dahlström U; Fu M; Lund LH
    JACC Heart Fail; 2017 Aug; 5(8):565-574. PubMed ID: 28711451
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum.
    Lund LH; Claggett B; Liu J; Lam CS; Jhund PS; Rosano GM; Swedberg K; Yusuf S; Granger CB; Pfeffer MA; McMurray JJV; Solomon SD
    Eur J Heart Fail; 2018 Aug; 20(8):1230-1239. PubMed ID: 29431256
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biomarker Profiles of Acute Heart Failure Patients With a Mid-Range Ejection Fraction.
    Tromp J; Khan MAF; Mentz RJ; O'Connor CM; Metra M; Dittrich HC; Ponikowski P; Teerlink JR; Cotter G; Davison B; Cleland JGF; Givertz MM; Bloomfield DM; Van Veldhuisen DJ; Hillege HL; Voors AA; van der Meer P
    JACC Heart Fail; 2017 Jul; 5(7):507-517. PubMed ID: 28624483
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Longitudinal evaluation of ventricular ejection fraction and NT-proBNP across heart failure subgroups.
    Martinsson A; Oest P; Wiborg MB; Reitan Ö; Smith JG
    Scand Cardiovasc J; 2018 Aug; 52(4):205-210. PubMed ID: 29656687
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.